Smith-and-Nephew SNATS is a medical devices business based in the US. Smith-and-Nephew SNATS shares (SNN) are listed on the NYSE and all prices are listed in US Dollars. Smith-and-Nephew SNATS employs 17,000 staff and has a trailing 12-month revenue of around $5.9 billion.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Smith-and-Nephew SNATS stock price (NYSE: SNN)
Use our graph to track the performance of SNN stocks over time.
Is it a good time to buy Smith-and-Nephew SNATS stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Smith-and-Nephew SNATS stock undervalued or overvalued?
Valuing Smith-and-Nephew SNATS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Smith-and-Nephew SNATS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Smith-and-Nephew SNATS's P/E ratio
Smith-and-Nephew SNATS's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, Smith-and-Nephew SNATS shares trade at around 30x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Smith-and-Nephew SNATS's PEG ratio
Smith-and-Nephew SNATS's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6471. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Smith-and-Nephew SNATS's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Smith-and-Nephew SNATS's EBITDA
Smith-and-Nephew SNATS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.4 billion.
The EBITDA is a measure of a Smith-and-Nephew SNATS's overall financial performance and is widely used to measure a its profitability.
Smith-and-Nephew SNATS financials
Revenue TTM
$5.9 billion
Operating margin TTM
14.49%
Gross profit TTM
$4.2 billion
Return on assets TTM
5.81%
Return on equity TTM
9.14%
Profit margin
8.26%
Book value
$6.33
Market Capitalization
$14.2 billion
TTM: trailing 12 months
Smith-and-Nephew SNATS share dividends
Dividend payout ratio: 136.07% of net profits
Recently Smith-and-Nephew SNATS has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Smith-and-Nephew SNATS shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Smith-and-Nephew SNATS's case, that would currently equate to about $0.381 per share.
Smith-and-Nephew SNATS's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Smith-and-Nephew SNATS's most recent dividend payout was on 6 November 2025. The latest dividend was paid out to all shareholders who bought their shares by 2 October 2025 (the "ex-dividend date").
Have Smith-and-Nephew SNATS's shares ever split?
Smith-and-Nephew SNATS's shares were
split on a 2499:1000 basis on 14 October 2014
. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 2499 shares. This wouldn't directly have changed the overall worth of your Smith-and-Nephew SNATS shares – just the quantity. However, indirectly, the new 60% lower share price could have impacted the market appetite for Smith-and-Nephew SNATS shares which in turn could have impacted Smith-and-Nephew SNATS's share price.
Smith-and-Nephew SNATS share price volatility
Over the last 12 months, Smith-and-Nephew SNATS's shares have ranged in value from as little as $23.113 up to $38.4708. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Smith-and-Nephew SNATS's is 0.655. This would suggest that Smith-and-Nephew SNATS's shares are less volatile than average (for this exchange).
Smith-and-Nephew SNATS overview
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers.
Frequently asked questions
What percentage of Smith-and-Nephew SNATS is owned by insiders or institutions? Currently 0.036% of Smith-and-Nephew SNATS shares are held by insiders and 7.682% by institutions.How many people work for Smith-and-Nephew SNATS? Latest data suggests 17,000 work at Smith-and-Nephew SNATS.When does the fiscal year end for Smith-and-Nephew SNATS? Smith-and-Nephew SNATS's fiscal year ends in December.Where is Smith-and-Nephew SNATS based? Smith-and-Nephew SNATS's address is: Building 5, Watford, United Kingdom, WD18 8YEWhat is Smith-and-Nephew SNATS's ISIN number? Smith-and-Nephew SNATS's international securities identification number is: US83175M2052What is Smith-and-Nephew SNATS's CUSIP number? Smith-and-Nephew SNATS's Committee on Uniform Securities Identification Procedures number is: 83175M106
Discover the best stock picking services based on expert analysis, pricing, and strategy fit. Compare top tools to find the right service for your investing style in 2025.
SoFi Invest is a zero commissions platform with both active and automated investment accounts.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
